13490-69-2

Usage

Uses

Used in Pain Relief Applications:
(αS)-α-Isopropylbenzeneacetic acid is used as a pain reliever for conditions such as headaches, menstrual cramps, and minor injuries. It helps to alleviate pain by reducing the levels of prostaglandins in the body.
Used in Anti-Inflammatory Applications:
(αS)-α-Isopropylbenzeneacetic acid is used as an anti-inflammatory agent to treat conditions characterized by inflammation, such as arthritis. It works by inhibiting the production of prostaglandins, which are involved in the inflammatory process.
Used in Over-the-Counter Medications:
(αS)-α-Isopropylbenzeneacetic acid is used as an active ingredient in various over-the-counter medications, providing relief from pain and inflammation for a wide range of conditions.
Used in Prescription Medications:
(αS)-α-Isopropylbenzeneacetic acid is also found in some prescription medications, where it may be combined with other drugs to provide enhanced pain relief and anti-inflammatory effects.
Used in Topical Gels:
(αS)-α-Isopropylbenzeneacetic acid is used in topical gels, allowing for localized treatment of pain and inflammation, particularly for muscle and joint pain.
However, it is important to note that (αS)-α-Isopropylbenzeneacetic acid can cause side effects such as stomach irritation, heartburn, and dizziness. It should be used with caution, especially in individuals with certain medical conditions or those taking other medications.

InChI:InChI=1/C11H14O2/c1-8(2)10(11(12)13)9-6-4-3-5-7-9/h3-8,10H,1-2H3,(H,12,13)/t10-/m0/s1

Upstream product

• 4412-08-2 3-methyl-2-phenylbut-2-enoic acid 
• 72615-27-1 2-phenyl-3-methylbutyric acid methyl ester 
• 134837-57-3 (S)-1-{[Dimethyl-((E)-(R)-4-methyl-3-phenyl-pent-1-enyl)-silanyl]-methyl}-2-methoxymethyl-pyrrolidine 
• 103-82-2 phenylacetic acid 
• 75-26-3 isopropyl bromide 
• 3508-94-9 3-methyl-2-phenylbutyric acid 
• 124931-92-6 (S)-3-Methyl-2-phenyl-butyric acid 2'-hydroxy-[1,1']binaphthalenyl-2-yl ester 
• 222021-01-4 {(R)-1-[(2R,5S)-2-Isopropyl-5-methyl-cyclohex-(E)-ylidenemethyl]-2-methyl-propyl}-benzene 
• 5558-29-2 3-methyl-2-phenyl-butyronitrile 
• 300-57-2 allylbenzene 
• 13491-00-4 (S)-3-methyl-2-phenyl-butyric acid (S)-1-phenylethylamine salt 
• 75-30-9 2-iodo-propane 
• 134837-46-0 cinnamyldimethyl-<(S)-2-methoxymethylpyrrolidinylmethyl>silane 
• 134837-45-9 chloromethyl(cinnamyl)dimethylsilane 

Downstream Products

• 19079-80-2 ethyl (S)-3-methyl-2-phenylbutanoate 
• 19643-71-1 (2S)-3-methyl-2-phenylbutan-1-ol 
• 934838-62-7 N-benzyloxy-4-(3-methyl-2-phenyl-butyrylamino)-benzamide 
• 935881-37-1 AR-42 
• 36667-53-5 (-)-S-4-Phenyl-5-methyl-1-hexen 
• 36667-54-6 (-)-S-5-Phenyl-6-methyl-1-hepten 
• 36617-73-9 (+'-(S)-1-Chlor-2-phenyl-3-methyl-butan 
• 1337959-58-6 C₁₂H₁₃NOS₂ 
• 1337959-76-8 C₂₂H₂₆O₂S₂ 
• 174290-51-8 (S)-3-methyl-2-phenylbutyramide 
• 1337959-57-5 C₁₂H₁₃NOS₂ 

Relevant academic research and scientific papers

Deracemizing α-Branched Carboxylic Acids by Catalytic Asymmetric Protonation of Bis-Silyl Ketene Acetals with Water or Methanol

We report a highly enantioselective catalytic protonation of bis-silyl ketene acetals. Our method delivers α-branched carboxylic acids, including nonsteroidal anti-inflammatory arylpropionic acids such as Ibuprofen, in high enantiomeric purity and high yields. The process can be incorporated in an overall deracemization of α-branched carboxylic acids, involving a double deprotonation and silylation followed by the catalytic asymmetric protonation.

HDAC3-SELECTIVE INHIBITORS

Disclosed herein are selective HDAC inhibitors. In some embodiments, the compounds are selective HDAC3 inhibitors. The compounds are useful to treat a variety of conditions, including cancers, i.e., breast cancer, cachexia, and liver steatosis.

Targeting breast cancer stem cells by novel HDAC3-selective inhibitors

Although histone deacetylase (HDAC) inhibitors have been known to suppress the cancer stem cell (CSC) population in multiple types of cancer cells, it remains unclear which HDAC isoforms and corresponding mechanisms contribute to this anti-CSC activity. Pursuant to our previous finding that HDAC8 regulates CSCs in triple-negative breast cancer (TNBC) cells by targeting Notch1 stability, we investigated related pathways and found HDAC3 to be mechanistically linked to CSC homeostasis by increasing β-catenin expression through the Akt/GSK3β pathway. Accordingly, we used a pan-HDAC inhibitor, AR-42 (1), as a scaffold to develop HDAC3-selective inhibitors, obtaining the proof-of-concept with 18 and 28. These two derivatives exhibited high potency and isoform selectivity in HDAC3 inhibition. Equally important, they showed in vitro and/or in vivo efficacy in suppressing the CSC subpopulation of TNBC cells via the downregulation of β-catenin.

Iridium-catalyzed enantioselective hydrogenation of α,β- unsaturated carboxylic acids with tetrasubstituted olefins

A highly efficient asymmetric hydrogenation of α,β-unsaturated carboxylic acids with tetrasubstituted olefin catalyzed by chiral spiro iridium complexes has been developed for the preparation of chiral α-substituted carboxylic acids in excellent enantioselectivities (up to 99% ee).

Highly enantioselective direct alkylation of arylacetic acids with chiral lithium amides as traceless auxiliaries

A direct, highly enantioselective alkylation of arylacetic acids via enediolates using a readily available chiral lithium amide as a stereodirecting reagent has been developed. This approach circumvents the traditional attachment and removal of chiral auxiliaries used currently for this type of transformation. The protocol is operationally simple, and the chiral reagent is readily recoverable.

Efficient parallel resolution of pentafluorophenyl active esters using quasi-enantiomeric combinations of oxazolidin-2-ones

The parallel resolution of racemic pentafluorophenyl 2-aryl/ phenylpropanoates and butanoates using an equimolar combination of quasi-enantiomeric Evans oxazolidin-2-ones is discussed. The levels of diastereoselectivity were excellent (>90% de) leading to separable quasi-enantiomeric oxazolidin-2-ones in good yield. This methodology was used to resolve a series of structurally related 2-aryl/phenylpropanoic and butanoic acids.

Enantiopure tert-butyl(phenyl)phosphine oxide. Chirality-recognition ability and mechanism

When enantiopure tert-butyl(phenyl)phosphine oxide 1 was used as a resolving agent, it showed an acceptable to good chirality-recognition ability for several kinds of racemic carboxylic acids 2. A study on a chirality-recognition mechanism based on X-ray crystallographic analyses of the diastereomeric complexes of 2 with 1 revealed that the complex crystals consisted of helical columns and that 1 was not responsible for the formation of the helical column and occupied a void between the columns; although 1 interacted with 2 via a hydrogen bond to primarily form a pair with 2, the complex crystals were mainly stabilized by the accumulation of weak interactions, such as CH/π, π/π and CH...O interactions, between 1/1, 1/2 and 2/2.

Introduction of single mutation changes arylmalonate decarboxylase to racemase

The introduction of only one mutation based on the estimated reaction mechanism endowed arylmalonate decarboxylase with a racemase activity, which catalyses racemisation of α-arylpropionates. The Royal Society of Chemistry 2006.

QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS

The invention relates to novel quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).

Rational design of CH/π interaction sites in a basic resolving agent

A novel synthetic basic resolving agent, cis-1-aminobenz[f]indan-2-ol (ABI), was rationally designed by introducing effective CH/π interaction sites to cis-1-aminoindan-2-ol (AI), whose chiral recognition ability has been reported from our laboratory. ABI was applicable to a wide variety of racemic arylalkanoic acids and showed moderate to excellent chiral recognition ability, which was obviously higher than that of AI. The fundamental and important role of CH/π interactions, such as tunable CH(sp2)/π and CH(sp 3)/π interactions, in the chiral recognition by ABI was revealed by X-ray crystallographic study.